GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.
China's Neusoft will receive $610 million from a variety of investors including Goldman Sachs to fund its medical imaging and healthcare IT ambitions.
Zoetis declared on Wednesday that its first-quarter 2015 dividend would be 8.3 cents per share, marking a 15% increase over this year's dividend rate.
Myriad Genetics lost big in its fight to keep competing breast cancer DNA tests off the market, as a U.S. appeals court ruled that its patents are not eligible for legal protection.
A pair of European diagnostics companies have wrapped up venture financings. Autoimmune diagnostician Protagen had a first close of a €10 million ($12.5 million) financing, while cancer genomic diagnostics company, 14M Genomics, a spinout of the Wellcome Trust Sanger Institute, got £12.5 million ($19.6 million).
Small cap Cerus gained more than 10% in early trading on Dec. 17 after the FDA approved its Intercept Blood System for plasma. This is the first pathogen-reduction system approved by the regulator to prepare plasma to reduce the risk of transfusion-transmitted infections.
Weeks after Belgium's UCB announced that it would sell its U.S. generic drug business for $1.53 billion, the company is calling off the sale in light of regulatory pushback over one of the unit's products.
Back in November, Salix revealed some inventory issues that had skewed perceived demand for some of its products--and possibly cost it a deal with Allergan in the process. Now, the company says it's moving to fix the problem quickly. But in the meantime, its top line will pay the price.
Medtronic has launched NovaShield Injectable Nasal Packing and Stent for functional endoscopic sinus surgery after an FDA approval in October. It's a gel made from chitosan that's placed in the sinus or nasal cavities after the surgery.
Israeli medical device company InSightec closed a $59 million Series D round led by major institutional investors in the U.S. and Asia. It's left room for existing shareholders to invest an additional $3.5 million through the end of January.